CTS2190 Phase I /II Clinical Study in Patients

Summary

This is a first in human study in patients with advanced or metastatic solid tumors. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific tumor types. The study drug, CTS2190, is a PRMT1 inhibitor administered orally. The study is planned to treat up to 224 participants.

Timeline

Start

2023-06-26

Primary completion

2025-07-31

Completion

2025-10-31

Drugs

Indications